id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
51,,,,,,,,,,,,,,,2024-05-05T18:02:14+06:00,BSH - H12304335388,Right,Trastuzumab,2024-03-19,,"Adjuvant ChT 4 cycles with AC from 16/04/23 to 18/06/23 > 4 cycles with Docetaxel &
Trastuzumab from 09.07.23 to 10.09.23, Maintenance 9 (Total 13) with Trastuzumab is due on 19.03.24",2024-02-04,,2024-04-06,,,,,Breast,48,,BSBSC-240000048,MRS. ROWSHAN ARA,1711536903,1968-04-12,Female,,,,,Dr Md Arifur Rahman,BSH,2.0,Continuous Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.5- Lower-outer quadrant of breast,Breast,Right,,,Stable,Alive,,,,,,,,,,,,,,,,,,,,,,
